Author

Markus Näpflin

Observed name: Näpflin, Markus

Institution: Helsana Group (Switzerland)

Observed institutions: University Hospital Zurich, Helsana Group (Switzerland), ZHAW Zurich University of Applied Sciences

ORCID: 0009-0009-2213-0424

Observed ORCID: 0009-0009-2213-0424

OpenAlex ID: A5072381746

Test–retest reliability of resting EEG spectra validates a statistical signature of persons

2007 · Markus Näpflin, Marc Wildi, et al. · Clinical Neurophysiology · 197

Test–retest reliability of EEG spectra during a working memory task

2008 · Markus Näpflin, Marc Wildi, et al. · NeuroImage · 58

Prevalence, trends, and individual patterns of long-term antidepressant medication use in the adult Swiss general population

2023 · Melanie A. Amrein, Michael P. Hengartner, et al. · European Journal of Clinical Pharmacology · 26

PDF

Trends in Micronutrient Laboratory Testing in Switzerland: A 7-Year Retrospective Analysis of Healthcare Claims Data

2020 · Carola A Huber, Michael Nagler, et al. · International Journal of General Medicine · 16

PDF

Are Tumor Marker Tests Applied Appropriately in Clinical Practice? A Healthcare Claims Data Analysis

2023 · Sabrina Stollberg, Markus Näpflin, et al. · Diagnostics · 14

PDF

Continuity of Care in Swiss Cancer Patients Using Claims Data

2020 · Eva Blozik, Caroline Bähler, et al. · Patient Preference and Adherence · 12

PDF

Continuity of care and treatment intensity at the end of life in Swiss cancer patients

2023 · Caroline Bähler, Markus Näpflin, et al. · European Journal of Public Health · 8

PDF

Does hospital volume affect outcomes after abdominal cancer surgery: an analysis of Swiss health insurance claims data

2022 · Kevin Wirth, Markus Näpflin, et al. · BMC Health Services Research · 6

PDF

Trends in Prescription of Stimulants and Narcoleptic Drugs in Switzerland: Longitudinal Health Insurance Claims Analysis for the Years 2014-2021

2024 · Tamara Scharf, Carola A Huber, et al. · JMIR Public Health and Surveillance · 4

PDF

Change in Colorectal Cancer Tests Submitted for Reimbursement in Switzerland 2012–2018: Evidence from Claims Data of a Large Insurance

2021 · Rémi Schneider, Markus Näpflin, et al. · International Journal of Public Health · 4

Treatment patterns in patients using triptan and prophylactic medication: an analysis of clinical practice prior to the introduction of CGRP antagonists

2019 · Carola A. Huber, Reto Agosti, et al. · Journal of Pain Research · 4

PDF

Initial prescriptions and medication switches of biological products: an analysis of prescription pathways and determinants in the Swiss healthcare setting

2023 · Kevin Wirth, Stefan Boes, et al. · BMJ Open · 3

PDF

Opioid prescriptions after knee replacement: a retrospective study of pathways and prognostic factors in the Swiss healthcare setting

2023 · Kevin Wirth, Caroline Bähler, et al. · BMJ Open · 2

PDF

Pharmaceutically treated comorbidities and associated healthcare costs among triptan users in Switzerland: A pharmacoepidemiological study from a nationwide health insurance database

2019 · Carola A. Huber, Reto Agosti, et al. · Pharmacoepidemiology and Drug Safety · 2

Long-Term Antidepressant Use and Dementia Risk: A Propensity Score-Matched Study of Swiss Older Adults, with an Anticholinergic-Specific Analysis

2026 · Melanie A. Amrein, Michael P. Hengartner, et al. · Drugs - Real World Outcomes

PDF

Prevalence and patterns of anti-angiogenic treatment discontinuation in neovascular age-related macular degeneration—insights from health claims data

2026 · Nicolas S. Bodmer, Livia Faes, et al. · Eye

Works count: 27

Citation count: 356

H-index: 7

I10-index: 6